CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:



Formula (I),

wherein:

R^1 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6cyanoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

X is N or CR^2;

R^2 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

or R^1 and R^2 are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one or more R;

Z is N or CR^4;

R^4 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

Y is N or CR^5;

R^5 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

R^6 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

each R^7 is independently hydrogen, deuterium, fluoro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or two R^7 are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with one or more R;

n is 1 or 2;

each R^8 is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or two R^8 on the same carbon are taken together to form an oxo;

or two R^8 on the same carbon or adjacent carbons are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R;

p is 0-4;

W is absent, $-C(R^9)_2-$, -O-, -S-, $-S(=O)-$, $-S(=O)_2-$, $-S(=O)(=NR^W)-$, or $-NR^W-$;

each R^9 is independently hydrogen, deuterium, halogen, -CN, -OH, $-OR^a$, $-NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or two R^9 are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with one or more R;

R^W is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

each R^{10} is independently deuterium, halogen, -CN, $-NO_2$, -OH, $-OR^a$, $-OC(=O)R^a$, $-OC(=O)OR^b$, $-OC(=O)NR^cR^d$, -SH, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, $-NR^bS(=O)_2R^a$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

q is 0-4;

each R^a is independently C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

each R^b is independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

each R^c and R^d are independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

or R^c and R^d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; and

each R is independently deuterium, halogen, -CN, -OH, -OC_1-C_6alkyl, -S(=O)C_1-C_6alkyl, -$S(=O)_2C_1$-C_6alkyl, -$S(=O)_2NH_2$, -$S(=O)_2NHC_1$-C_6alkyl, -$S(=O)_2N(C_1$-C_6alkyl$)_2$, -NH_2, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -NHC(=O)OC_1-C_6alkyl, -C(=O)C_1-C_6alkyl, -C(=O)OH, -C(=O)OC_1-C_6alkyl, -$C(=O)NH_2$, -$C(=O)N(C_1$-C_6alkyl$)_2$, -$C(=O)NHC_1$-C_6alkyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl; or two R on the same atom form an oxo;

provided that the compound of Formula (I) is not , , or .

2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 is hydrogen, deuterium, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, or cycloalkyl;
optionally wherein R^1 is C_1-C_6alkyl or cycloalkyl;
optionally wherein R^1 is C_1alkyl or C_3-C_6alkyl;
optionally wherein R^1 is cycloalkyl;
optionally wherein R^1 is methyl or ethyl;
optionally wherein R^1 is ethyl;
optionally wherein R^1 is halogen.
3. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is N.
4. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is CR^2.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^2 is hydrogen, deuterium, halogen, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein R^2 is hydrogen or C_1-C_6alkyl;
optionally wherein R^2 is hydrogen;
6. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 and R^2 are taken together to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with deuterium, halogen, -CN, -OH, -OR^a, -NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl.
7. A compound of Formula (II), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:



Formula (II),

wherein:

Ring B taken with X^1 and X^2 is a 5-membered heterocycloalkyl or a 5-membered heteroaryl;

X^1 is C, CH, or N;

X^2 is C, CH, or N;

each R^{11} is independently hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6cyanoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

m is 0-3;

Z is N or CR^4;

R^4 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

Y is N or CR^5;

R^5 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

R^6 is hydrogen, deuterium, halogen, -CN, -OH, -OR^a, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

each R^7 is independently hydrogen, deuterium, fluoro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or two R^7 are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with one or more R;

n is 1 or 2;

each R^8 is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or two R^8 on the same carbon are taken together to form an oxo;

or two R^8 on the same carbon or adjacent carbons are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R;

p is 0-4;

W is absent, -$C(R^9)_2$-, -O-, -S-, -S(=O)-, -$S(=O)_2$-, -S(=O)(=NR^W)-, or -NR^W-;

each R^9 is independently hydrogen, deuterium, halogen, -CN, -OH, -OR^a, -NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or two R^9 are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with one or more R;

R^W is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

each R^{10} is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

q is 0-4;

each R^a is independently C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

each R^b is independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

each R^c and R^d are independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently and optionally substituted with one or more R;

or R^c and R^d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; and

each R is independently deuterium, halogen, -CN, -OH, -OC_1-C_6alkyl, -$S(=O)C_1$-C_6alkyl, -$S(=O)_2C_1$-C_6alkyl, -$S(=O)_2NH_2$, -$S(=O)_2NHC_1$-C_6alkyl, -$S(=O)_2N(C_1$-C_6alkyl$)_2$, -NH_2, -NHC_1-C_6alkyl, -$N(C_1$-C_6alkyl$)_2$, -$NHC(=O)OC_1$-C_6alkyl, -$C(=O)C_1$-C_6alkyl, -C(=O)OH, -$C(=O)OC_1$-C_6alkyl, -$C(=O)NH_2$, -$C(=O)N(C_1$-C_6alkyl$)_2$, -$C(=O)NHC_1$-C_6alkyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or two R on the same atom form an oxo.

8. The compound of claim 7, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring B taken with X^1 and X^2 is a 5-membered heterocycloalkyl.

9. The compound of claim 7, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring B taken with X^1 and X^2 is a 5-membered heteroaryl.

10. The compound of any one of claims 7-9, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X^1 is C;
optionally wherein X^1 is CH.

11. The compound of any one of claims 7-9, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X^1 is N.

12. The compound of any one of claims 7-11, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X^2 is C;
optionally wherein X^2 is CH.

13. The compound of any one of claims 7-11, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X^2 is N.

14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is N.

15. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is CR^4.

16. The compound of any one of claims 1-13 or 14, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^4 is hydrogen, deuterium, halogen, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein R^4 is hydrogen or C_1-C_6alkyl;
optionally wherein R^4 is hydrogen.

17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Y is N.

18. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Y is CR^5.

19. The compound of any one of claims 1-16 or 18, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^5 is hydrogen, deuterium, halogen, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein R^5 is hydrogen or C_1-C_6alkyl;
optionally wherein R^5 is hydrogen.

20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^6 is hydrogen, deuterium, halogen, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein R^6 is hydrogen or C_1-C_6alkyl;
optionally wherein R^6 is hydrogen.

21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^7 is independently hydrogen, deuterium, fluoro, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein each R^7 is independently hydrogen, deuterium, fluoro, or C_1-C_6alkyl;
optionally wherein each R^7 is hydrogen;
optionally wherein two R^7 are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with deuterium, halogen, -CN, -OH, -OR^a, -NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl.
22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein n is 1.
23. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein n is 2.
24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^8 is independently deuterium, halogen, -CN, -OH, -OR^a, -NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein each R^8 is independently deuterium, halogen, -CN, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein each R^8 is independently C_1-C_6alkyl;
optionally wherein two R^8 on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more deuterium, halogen, -CN, -OH, -OR^a, -NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;
optionally wherein two R^8 on adjacent carbons are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more deuterium, halogen, -CN, -OH, -OR^a, -NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl.
25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein p is 1-4;
optionally wherein p is 1 or 2;
optionally wherein p is 1;
optionally wherein p is 2.
26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein W is -$C(R^9)_2$-, -O-, or -NR^W-;
optionally wherein W is -O- or -NR^W-;
optionally wherein W is -S-, -S(=O)-, -$S(=O)_2$-, or -S(=O)(=NR^W)-;
optionally wherein W is -O-;

optionally wherein W is -NR^{W2}-.

27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^9 is independently hydrogen, deuterium, fluoro, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;
optionally wherein each R^9 is independently hydrogen, deuterium, fluoro, or C_1-C_6alkyl;
optionally wherein each R^9 is hydrogen;
optionally wherein two R^9 are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with deuterium, halogen, -CN, -OH, -OR^a, -NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl.

28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^W is hydrogen or C_1-C_6alkyl;
optionally wherein each R^W is hydrogen.

29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is cycloalkyl or heterocycloalkyl;
optionally wherein Ring A is aryl or heteroaryl;
optionally wherein Ring A is phenyl;
optionally wherein Ring A is heteroaryl;
optionally wherein Ring A is 5- or 6-membered heteroaryl;
optionally wherein Ring A is 5-membered heteroaryl;
optionally wherein Ring A is 6-membered heteroaryl;
optionally wherein Ring A is not 

.

30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^{10} is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;
provided that one R^{10} is not -$C(=O)NHCH_3$;
optionally wherein each R^{10} is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)OR^b$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

optionally wherein each R^{10} is independently deuterium, halogen, -CN, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, cycloalkyl, or heterocycloalkyl;

optionally wherein each R^{10} is independently deuterium, halogen, -CN, -$OC(=O)NR^cR^d$, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl;

optionally wherein each R^{10} is independently deuterium, halogen, -CN, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, or C_1-C_6deuteroalkyl.

31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein q is 1-4;

optionally wherein q is 1 or 2;

optionally wherein q is 1;

optionally wherein q is 2.

32. A compound selected from:

Example #	Structure
1	
2	
3	
4	
5	

Example #	Structure
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	

Example #	Structure
17	
18	
19	
20	
21	
22	
23	

Example #	Structure
24	
25	
26	
27	
28	
29	
30	
31	

Example #	Structure
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	

Example #	Structure
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	

Example #	Structure
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	

Example #	Structure
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	

Example #	Structure
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	

Example #	Structure
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	

Example #	Structure
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	
108	

Example #	Structure
109	
110	
111	
112	
113	
114	
115	
116	
117	

Example #	Structure
118	
119	
120	
121	

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

33. A pharmaceutical composition comprising a compound of any one of claims 1-32, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.

34. Use of the compounds of any one of claims 1-32, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, for the manufacture of a medicament for the treatment of cancer.